For research use only. Not for therapeutic Use.
Dutogliptin (PHX-1149 free base) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.
Dutogliptin exhibits low plasma protein binding (11%) and is rapidly absorbed with a Tmax of 3-4 h and a half-life of 10-13 h. Dutogliptin is metabolically stable and does not inhibit or induce the activity of major CYP450s[2].
| Catalog Number | I013547 |
| CAS Number | 852329-66-9 |
| Synonyms | [(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid |
| Molecular Formula | C10H20BN3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1 |
| InChIKey | DVJAMEIQRSHVKC-BDAKNGLRSA-N |
| SMILES | B(C1CCCN1C(=O)CNC2CCNC2)(O)O |
| Reference | [1]. Marier JF, et al. Population pharmacokinetic analysis of dutogliptin, a selective dipeptidyl peptidase-4 inhibitor. Clin Pharmacol Drug Dev. 2014 Jul;3(4):297-304. [2]. Pattzi HM, et al. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. |
